Welcome to our dedicated page for Pluri news (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.
Pluri Inc (PLUR) pioneers transformative biotechnology solutions through its patented 3D cell expansion platform, driving innovations across regenerative medicine, immunotherapy, and sustainable food production. This dedicated news hub provides investors and industry professionals with timely updates on corporate developments, strategic partnerships, and technological breakthroughs.
Access essential updates including earnings announcements, regulatory milestones, and progress in key sectors such as cultivated meat production through subsidiary Ever After Foods. Track advancements in off-the-shelf cell therapies for medical applications and manufacturing collaborations through Pluri's CDMO division.
Our curated news collection serves as your primary source for understanding Pluri's multi-industry impact. Discover updates on clinical trial progress, foodtech innovations, and manufacturing expansions while maintaining awareness of market-moving developments. Bookmark this page for streamlined access to press releases and analysis-free corporate announcements directly from verified sources.
Pluri Inc. (Nasdaq: PLUR) has unveiled a revolutionary cell manufacturing system called PluriMatrix, which significantly boosts cell production efficiency and scalability, addressing a major challenge in cell-based industries such as pharma, biologics, foodtech, and agri-tech. This patented 3D cell expansion technology is designed to enhance productivity, with Ever After Foods, a subsidiary, anticipating a remarkable 700% increase in productivity for cultivated meat production. The modular system not only reduces the ecological footprint but also lowers infrastructure costs. CEO Yaky Yanay emphasized the system's potential to bring substantial benefits to health and food safety while expanding Pluri’s market reach. This breakthrough positions Pluri to capitalize on its technological advances through industry collaborations.
Pluri Inc. (Nasdaq: PLUR) successfully achieved proof of concept in its joint venture with Tnuva Group for cultivated meat products, utilizing its proprietary 3D cell-based technology. The company launched a new strategy focusing on sustainability and innovative cell-based solutions across various sectors. Pluri is strengthening its financial position through cost-cutting measures and collaboration efforts, including a new partnership in biologics with a leading European manufacturer. The cultivated meat market is projected to reach $140 billion by 2030, positioning Pluri as a potential leader in this expanding industry.
Pluri Inc. (Nasdaq: PLUR) announced the execution of securities purchase agreements for the sale of 7,885,900 common shares and warrants. Shares were sold at prices ranging from $1.03 to $1.06, with a total expected closing date by January 31, 2023. CEO Yaky Yanay will forgo $375,000 of his annual salary for equity grants. The offerings were made under SEC exemptions and are not registered under the Securities Act. Pluri is focused on developing cellular solutions for various industries, including regenerative medicine and food-tech.
FAQ
What is the current stock price of Pluri (PLUR)?
What is the market cap of Pluri (PLUR)?
